Helicobacter Pylori Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Current research on the interaction between Helicobacter pylori and macrophages
Mol Biol Rep. 2024 Apr 10;51(1):497. doi: 10.1007/s11033-024-09395-8.ABSTRACTHelicobacter pylori (H. pylori) is a gram-negative bacteria with a worldwide infection rate of 50%, known to induce gastritis, ulcers and gastric cancer. The interplay between H. pylori and immune cells within the gastric mucosa is pivotal in the pathogenesis of H. pylori-related disease. Following H. pylori infection, there is an observed increase in gastric mucosal macrophages, which are associated with the progression of gastritis. H. pylori elicits macrophage polarization, releases cytokines, reactive oxygen species (ROS) and nitric oxide (NO)...
Source: Molecular Biology Reports - April 10, 2024 Category: Molecular Biology Authors: Yan-Fei Wei Si-An Xie Shu-Tian Zhang Source Type: research

Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori : Current perspectives and implications
World J Gastroenterol. 2024 Mar 14;30(10):1280-1286. doi: 10.3748/wjg.v30.i10.1280.ABSTRACTYu et al's study in the World Journal of Gastroenterology (2023) introduced a novel regimen of Vonoprazan-amoxicillin dual therapy combined with Saccharomyces boulardii (S. boulardii) for the rescue therapy against Helicobacter pylori (H. pylori), a pathogen responsible for peptic ulcers and gastric cancer. Vonoprazan is a potassium-competitive acid blocker renowned for its rapid and long-lasting acid suppression, which is minimally affected by mealtime. Compared to proton pump inhibitors, which bind irreversibly to cysteine residues...
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Valerie Josephine Dirjayanto Jessica Audrey Daniel Martin Simadibrata Source Type: research

Estimates of global and regional prevalence of Helicobacter pylori infection among individuals with obesity: a systematic review and meta-analysis
ConclusionThe findings have the potential to influence future health policies for preventing and treatingH. pylori infection. However, there is variability among the included studies, indicating the need for more population-based research. (Source: Infection)
Source: Infection - April 10, 2024 Category: Infectious Diseases Source Type: research

Quality appraisal of clinical guidelines for Helicobacter pylori infection and systematic analysis of the level of evidence for recommendations
ConclusionThe overall quality of CPGs for HP infection is poor, and CPG developers tend to neglect some domains, resulting in a wide variability in the quality of the CPGs. Additionally, CPGs for HP infection lack sufficient high-quality evidence, and the grading of recommendation strength should be based on the quality of evidence. The CPGs for HP infection have much room for improvement and further researches are required to minimize the evidence gap. (Source: PLoS One)
Source: PLoS One - April 10, 2024 Category: Biomedical Science Authors: Jiayin Ou Source Type: research

Chemical constituents of the aerial parts of Mitracarpus hirtus (L.) DC (Rubiaceae)
Nat Prod Res. 2024 Apr 8:1-7. doi: 10.1080/14786419.2024.2337110. Online ahead of print.ABSTRACTA phytochemical investigation of the aerial parts of Mitracarpus hirtus afforded thirteen compounds, including a new naphthoquinone di-glycoside (1), three isopentenyl isoflavones (2-4), four flavonoids (5-8), three iridoid glycosides (9 - 11) and two coumarins (12 and 13). Their structures were elucidated based on extensive spectroscopic analyses, chemical methods, and the comparison with the literature. Among them, compound 1 possesses a 2-(3-methylnaphthalen-2-yl)acetic acid core with two glucosyl groups, compounds 2-4 are th...
Source: Natural Product Research - April 8, 2024 Category: Biochemistry Authors: Xinyi Wei Yingrun Ma Mingming Xu Ding Heng Monday M Onakpa Jin-Ao Duan Chun-Tao Che Hongkai Bi Junfei Zhou Ming Zhao Source Type: research

Engineering resveratrol-loaded chitosan nanoparticles for potential use against Helicobacter pylori infection
Eur J Pharm Biopharm. 2024 Apr 6:114280. doi: 10.1016/j.ejpb.2024.114280. Online ahead of print.ABSTRACTHelicobacter pylori (H. pylori) is a microorganism directly linked to severe clinical conditions affecting the stomach. The virulence factors and its ability to form biofilms increase resistance to conventional antibiotics, growing the need for new substances and strategies for the treatment of H. pylori infection. The trans-resveratrol (RESV), a bioactive polyphenol from natural sources, has a potential activity against this gastric pathogen. Here, Chitosan nanoparticles (NP) containing RESV (RESV-NP) were developed for...
Source: European Journal of Pharmaceutics and Biopharmaceutics - April 8, 2024 Category: Drugs & Pharmacology Authors: Larissa Sp ósito Diana Fonseca Suzana Gon çalves Carvalho Rafael Miguel S ábio Gabriel Marena Ta ís Maria Bauab Andr éia Bagliotti Meneguin Paula Parreira M Cristina L Martins Marlus Chorilli Source Type: research